Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Entera Bio Ltd., a foreign private issuer, for the month of November 2021. The filing, dated November 10, 2021, incorporates by reference a press release issued on the same date. The registrant is headquartered in Jerusalem, Israel, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disseminate a press release and does not contain audited financial statements or specific financial data points for the period.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The document references an attached press release (Exhibit 99.1) but does not summarize its specific content or financial impact within the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the incorporated press release, the text of which is not included in the input provided.
Key Facts for Investor Verification
- Verify the specific content of the press release dated November 10, 2021, attached as Exhibit 99.1, as the Form 6-K itself contains no operational or financial details.
- Confirm the incorporation of this report into Registration Statements on Form F-3 (Numbers 333-238988 and 333-239843).
- Note that the filing was signed by Spiros Jamas, Sc.D., Chief Executive Officer and Director.